A multicenter, randomized, open-label, phase 3 study to compare the safety and effectiveness of doripenem versus a comparator antibiotic in hospital-acquired pneumonia

Trial Profile

A multicenter, randomized, open-label, phase 3 study to compare the safety and effectiveness of doripenem versus a comparator antibiotic in hospital-acquired pneumonia

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Doripenem (Primary) ; Piperacillin/tazobactam
  • Indications Bacterial infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
    • 06 Jun 2008 EMEA approved intital MAA for the treatment of adults with nonsocomial pneumonia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top